Recruiting
Phase 3

MPH HCl ER

Sponsor:

Ironshore Pharmaceuticals and Development, Inc

Code:

NCT06431256

Conditions

Attention Deficit Hyperactivity Disorder

Eligibility Criteria

Sex: All

Age: 4 - 5

Healthy Volunteers: Not accepted

Interventions

HLD200 methylphenidate hydrochloride capsules

Placebo HLD200 capsules

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Ironshore Pharmaceuticals and Development, Inc on 2025-03-19.